Literature DB >> 31520735

Signaling alterations caused by drugs and autophagy.

Paul Dent1, Laurence Booth2, Andrew Poklepovic3, John F Hancock4.   

Abstract

Autophagy is an evolutionary conserved process that recycles cellular materials in times of nutrient restriction to maintain viability. In cancer therapeutics, the role of autophagy in response to multi-kinase inhibitors, alone or when combined with histone deacetylase (HDAC) inhibitors acts, generally, to facilitate the killing of tumor cells. Furthermore, the formation of autophagosomes and subsequent degradation of their contents can reduce the expression of HDAC proteins themselves as well as of other signaling regulatory molecules such as protein chaperones and mutated RAS proteins. Reduced levels of HDAC6 causes the acetylation and inactivation of heat shock protein 90, and, together with reduced expression of the chaperones HSP70 and GRP78, generates a strong endoplasmic reticulum (ER) stress response. Prolonged intense ER stress signaling causes tumor cell death. Reduced expression of HDACs 1, 2 and 3 causes the levels of programed death ligand 1 (PD-L1) to decline and the expression of Class I MHCA to increase which correlates with elevated immunogenicity of the tumor cells in vivo. This review will specifically focus on the downstream implications that result from autophagic-degradation of HDACs, RAS and protein chaperones.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Autophagy; Chaperone; HDAC; Hippo; Neratinib; RAS; Rubicon

Year:  2019        PMID: 31520735     DOI: 10.1016/j.cellsig.2019.109416

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  9 in total

1.  Not the comfy chair! Cancer drugs that act against multiple active sites.

Authors:  Laurence Booth; Andrew Poklepovic; Paul Dent
Journal:  Expert Opin Ther Targets       Date:  2019-11-14       Impact factor: 6.902

2.  Cocaine-induced locomotor stimulation involves autophagic degradation of the dopamine transporter.

Authors:  Maged M Harraz; Prasun Guha; Evan R Semenza; Adarsha P Malla; In Guk Kang; Young Jun Song; Luke Reilly; Isaac Treisman; Pedro Cortés; Mark A Coggiano; Vijayabhaskar Veeravalli; Rana Rais; Gianluigi Tanda; Solomon H Snyder
Journal:  Mol Psychiatry       Date:  2021-01-07       Impact factor: 15.992

3.  Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.

Authors:  Lili Song; Shikai Liu; Sufen Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 4.  Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.

Authors:  Annamaria Colao; Filomena de Nigris; Roberta Modica; Claudio Napoli
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-15       Impact factor: 5.555

Review 5.  The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer.

Authors:  Daniela Trisciuoglio; Francesca Degrassi
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

Review 6.  Kinase inhibitors: look beyond the label on the bottle.

Authors:  Paul Dent; Andrew Poklepovic; Laurence Booth; John F Hancock
Journal:  Cancer Drug Resist       Date:  2019-12-19

7.  Endoplasmic Reticulum Stress-Related Signature Predicts Prognosis and Drug Response in Clear Cell Renal Cell Carcinoma.

Authors:  Yuke Zhang; Yancheng Song; Jiangwen Dai; Zhaoxiang Wang; Yuhao Zeng; Feng Chen; Peng Zhang
Journal:  Front Pharmacol       Date:  2022-07-26       Impact factor: 5.988

8.  Fingolimod Augments Monomethylfumarate Killing of GBM Cells.

Authors:  Paul Dent; Laurence Booth; Jane L Roberts; Andrew Poklepovic; John F Hancock
Journal:  Front Oncol       Date:  2020-01-28       Impact factor: 6.244

9.  Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.

Authors:  Paul Dent; Laurence Booth; Andrew Poklepovic
Journal:  Immunometabolism       Date:  2019-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.